Simulations Plus (SLP) Aktie Kurs
Simulations Plus Kurs
De seneste 19 år voksede Simulations Pluss omsætning med 14,7 % årligt og nåede 79,18 Mio. USD. Indtjening pr. aktie er vokset med 15,0 % om året de seneste 18 år. For Simulations Plus er nettoavance på -81,7 % ned i forhold til 21,1 % for et par år siden. Ved dagens kurs bliver direkteafkastet cirka 0,97 %. Udlodningsandelen er omkring 37 % af indtjeningen. Konsensus 12-måneders kursmål for Simulations Plus er 18,50 USD, cirka over kursen med 0,0 %. Af 12 analytikere anbefaler 0 køb — den samlede vurdering er Sælg.
Simulations Plus aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Simulations Plus aktie og aktieanalyse
Hyppigt stillede spørgsmål om Simulations Plus-aktien
Simulations Plus Inc is primarily active in the pharmaceutical and biotechnology industries. With a focus on simulation software and consulting services, the company provides cutting-edge solutions for drug discovery and development. Simulations Plus Inc's expertise in modeling and simulation technologies helps pharmaceutical companies optimize their drug formulation and dosage strategies. By leveraging their industry-leading software platforms, Simulations Plus Inc supports the efficient research and development of new therapies, enhancing the overall success and effectiveness of pharmaceutical companies.
The main competitors of Simulations Plus Inc in the market include Certara, Inc and Dassault Systèmes.
The business model of Simulations Plus Inc revolves around providing software and consulting services for pharmaceutical research and development. As a leading provider in the field of drug discovery and development, Simulations Plus Inc aims to enhance the efficiency and effectiveness of the pharmaceutical industry through their innovative solutions. By utilizing computer modeling and simulation software, the company assists in predicting and optimizing drug properties, interactions, and outcomes. This enables scientists and researchers to make informed decisions throughout the drug development process, leading to improved efficacy, safety, and reduced costs. Simulations Plus Inc's comprehensive solutions cater to the needs of pharmaceutical companies, regulatory agencies, and academia worldwide.
Simulations Plus Inc is a leading provider of simulation and modeling software for the pharmaceutical and biotechnology industries. Established in 1996, the company has amassed extensive expertise in the field. Simulations Plus Inc has developed a strong reputation for its cutting-edge technology and innovative solutions, helping pharmaceutical companies optimize drug discovery and development processes. With a focus on increasing efficiency and reducing costs, Simulations Plus Inc has become a trusted partner for numerous organizations worldwide. The company's commitment to excellence has earned them recognition and a loyal customer base. Simulations Plus Inc continues to drive advancements in the industry, delivering impactful software solutions that streamline drug development.
Simulations Plus Inc has achieved significant milestones throughout its history. Some notable accomplishments include the development and release of their industry-leading software solutions, such as GastroPlus™ and DDDPlus™, which have gained widespread recognition and adoption in the pharmaceutical industry. The company has also formed strategic partnerships and collaborations with top pharmaceutical companies, further establishing its presence and credibility in the market. Additionally, Simulations Plus Inc has a strong track record of achieving consistent revenue growth and delivering value to its shareholders. These achievements reflect the company's commitment to innovation, excellence, and meeting the evolving needs of the life sciences industry.
Simulations Plus Inc is primarily present in the United States.
Simulations Plus Inc represents values of innovation, scientific excellence, and customer satisfaction. With a corporate philosophy focused on advancing pharmaceutical research and enhancing drug development, Simulations Plus Inc strives to provide cutting-edge software and consulting services. By combining advanced technologies and domain knowledge, the company facilitates cost-effective and efficient drug discovery and development processes. Simulations Plus Inc is committed to delivering high-quality solutions, fostering collaborative relationships, and continuously improving its products and services.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 18,50 USD for Simulations Plus-aktien (median: 18,50 USD), svarende til +0,0 % i forhold til seneste kurs. Konsensus bygger på 12 analytikervurderinger.
12 analytikere vurderer i øjeblikket Simulations Plus-aktien: 0 anbefaler køb, 7 hold og 5 salg. For 2026 forventer analytikere, at Simulations Plus genererer omsætning på 81,80 Mio. USD og indtjening pr. aktie på 0,82 USD.
Omregnet til den aktuelle valutakurs handles Simulations Plus-aktien til 16,50 EUR (18,50 USD).
Simulations Plus-aktien (SLP) er noteret på 1 børser, herunder: NASDAQ (SLP).
Simulations Plus Inc. is a leading company in the field of simulation technology and software development. It provides solutions for researchers and experts in various industries, including biotechnology, pharmaceuticals, agriculture, food technology, and more. The company offers a range of products and tools for data analysis and innovative strategy development to bring new products and applications to the market. Some of its notable products include PK-SIM, MoBi, ADMET Predictor, GastroPlus, DILIsym, and MedChem Studio. Simulations Plus also offers solutions for the agricultural sector, such as Cartagenia, Crop Laptop, and Dose Response Toxicology. The company provides training and support to its customers, aiming to optimize their business processes. Its business model focuses on processing and analyzing large data sets to provide relevant insights and support decision-making processes. Simulations Plus aims to expand into new markets and develop products based on the latest technological advancements.
forventet-omsætningen for Simulations Plus er 81,80 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Simulations Plus er 16,48 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Simulations Plus er i øjeblikket 22,69. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Simulations Plus-aktien.
Pris-til-salgs-forholdet (P/S) for Simulations Plus er i øjeblikket 4,57. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Simulations Plus-aktien.
AlleAktien-kvalitetsscore for Simulations Plus er 3/10.
ISIN for Simulations Plus er US8292141053. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Simulations Plus er 924294. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Simulations Plus er SLP. Tickersymbolet bruges til at handle Simulations Plus-aktier på børsen.
Simulations Plus aktie
Simulations Plus Peer Group
Simulations Plus Ticker
Simulations Plus FIGI
Alle fundamentale data om Simulations Plus i deep dive
Vores aktieanalyse af Simulations Plus-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Simulations Plus. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: